News Celgene seals Juno acquisition for $9bn Celgene has today confirmed that it will acquire Juno Therapeutics for $9 billion, and says the move will make it a leader in cell immunotherapy.
Views & Analysis CAR-Ts dominated the agenda at ASH 2017 The American Society for Hematology congress was dominated by CAR-T therapies – their potential new uses, how to manage safety issues and bring these costly cellular treatments to patients.
News Celgene in talks to buy CAR-T partner Juno Celgene is understood to be in talks to buy CAR-T specialists Juno Therapeutics, in a deal which could be worth around $7 billion.
News Janssen jumps into CAR-T field with China’s Legend Biotech J&J has struck a deal with Chinese biotech company Genscript, giving it entry to the global market for CAR-T therapies.
News Gilead goes full throttle on CAR-Ts with $567m acquisition Gilead hopes CDL technology will create therapies targeting solid tumours
News UK offers meningitis jab to young people after outbreak The UK government has responded to calls to broaden vaccinations for meningitis B, offering the jab to "thousands" of young people this summer.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
